• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Advances in anatomic pathology >Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors
【24h】

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors

机译：评估实体瘤中的肿瘤浸润淋巴细胞：来自国际免疫肿瘤生物标志物工作组的病理学家和标准方法的实践审查：第2部分：直至黑色素瘤，胃肠道癌，非小细胞肺癌和间皮瘤 子宫内膜和卵巢癌，头部和颈部鳞状细胞癌，泌尿病癌和原发性脑肿瘤

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Assessment of the immune response to tumors is growing in importance as the prognostic implications of this response are increasingly recognized, and as immunotherapies are evaluated and implemented in different tumor types. However, many different approaches can be used to assess and describe the immune response, which limits efforts at implementation as a routine clinical biomarker. In part 1 of this review, we have proposed a standardized methodology to assess tumor-infiltrating lymphocytes (TILs) in solid tumors, based on the International Immuno-Oncology Biomarkers Working Group guidelines for invasive breast carcinoma. In part 2 of this review, we discuss the available evidence for the prognostic and predictive value of TILs in common solid tumors, including carcinomas of the lung, gastrointestinal tract, genitourinary system, gynecologic system, and head and neck, as well as primary brain tumors, mesothelioma and melanoma. The particularities and different emphases in TIL assessment in different tumor types are discussed. The standardized methodology we propose can be adapted to different tumor types and may be used as a standard against which other approaches can be compared. Standardization of TIL assessment will help clinicians, researchers and pathologists to conclusively evaluate the utility of this simple biomarker in the current era of immunotherapy.
机译：随着这种反应的预后意义越来越识别，对肿瘤的免疫反应的评估越来越重要，并且在不同肿瘤类型中评估和实施免疫治疗和实施免疫检查。然而，许多不同的方法可用于评估和描述免疫应答，这限制了作为常规临床生物标志物实施的努力。在本综述的第1部分中，我们提出了一种标准化的方法，以评估实体瘤中的肿瘤浸润淋巴细胞（直径），基于国际免疫肿瘤生物标志物工作组侵袭性乳腺癌的指导原则。在本综述的第2部分中，我们讨论了在常见的实体肿瘤中促进和预测值的可用证据，包括肺癌，胃肠道，泌尿生殖系统，妇科系统和头部和颈部以及原发性大脑的癌症肿瘤，间皮瘤和黑色素瘤。讨论了不同肿瘤类型的直到评估中的特殊性和不同的重点。我们提出的标准化方法可以适应不同的肿瘤类型，并且可以用作可以比较其他方法的标准。 TIL评估的标准化将有助于临床医生，研究人员和病理学家，以便在目前的免疫疗法时代评估这个简单的生物标志物的效用。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号